Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)

被引：0
|
作者：
Wang, M.
Bensinger, W.
Martin, T.
Alsina, M.
Siegel, D. S. D.
Gabrail, N. Y.
Hari, P.
Singhal, S.
Vescio, R. A.
Assouline, S. E.
Kunkel, L. A.
Vallone, M.
Wong, A.
Niesvizky, R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[5] John Theurer Canc Ctr, Hackensack, NJ USA
[6] Gabrail Canc Ctr, Canton, OH USA
[7] Med Coll Wisconsin, Miwaukee, WI USA
[8] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[10] McGill Univ, Jewish Gen Hosp, Clin Res Unit, Segal Canc Ctr,Lady Davis Inst, Montreal, PQ H3T 1E2, Canada
[11] ACT Biotech Inc, San Francisco, CA USA
[12] Onyx Pharmaceut, San Francisco, CA USA
[13] Onyx Pharmaceut, Emeryville, CA USA
[14] Cornell Univ, New York Presbyterian Hosp, Ctr Excellence Lymphoma & Myeloma, Weill Med Coll, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8025
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results
    Niesvizky, R.
    Bensinger, W.
    Vallone, M.
    Gutierrez, A.
    Kunkel, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] PX-171-006: PHASE IB MULTICENTER DOSE ESCALATION STUDY OF CARFILZOMIB (CFZ) PLUS LENALIDOMIDE (LEN) AND LOW DOSE DEXAMETHASONE (LODEX) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) - PRELIMINARY RESULTS
    Wang, M.
    Gutierrez, A.
    Niesvizky, R.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 431 - 431
  • [3] Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
    Wang, Michael
    Martin, Tom
    Bensinger, William
    Alsina, Melissa
    Siegel, David S.
    Kavalerchik, Edward
    Huang, Mei
    Orlowski, Robert Z.
    Niesvizky, Ruben
    BLOOD, 2013, 122 (18) : 3122 - 3128
  • [4] PX-171-006, A PHASE IB DOSE-ESCALATION STUDY OF CARFILZOMIB plus LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Wang, M.
    Bensinger, W.
    Orlowski, R.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrail, N.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 157
  • [5] Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
    Niesvizky, Ruben
    Martin, Thomas G., III
    Bensinger, William I.
    Alsina, Melissa
    Siegel, David S.
    Kunkel, Lori A.
    Wong, Alvin F.
    Lee, Susan
    Orlowski, Robert Z.
    Wang, Michael
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2248 - 2256
  • [6] Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma
    Wang, Michael
    Martin, Thomas
    Bensinger, William
    Alsina, Melissa
    Samuel, David
    Siegel, DiCapua
    Kavalerchik, Edward
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM)
    Bensinger, W.
    Wang, M.
    Orlowski, R. Z.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrall, N. Y.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] FINAL RESULTS FROM THE PHASE 1B/2 STUDY (PX-171-006) OF CARFILZOMIB (CFZ) IN COMBINATION WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (CRD) FOR PATIENTS WITH RELAPSED OR PROGRESSIVE MULTIPLE MYELOMA
    Niesvizky, R.
    Wang, M.
    Martin, T.
    Bensinger, W.
    Alsina, M.
    Siegel, D.
    Kavalerchik, E.
    HAEMATOLOGICA, 2013, 98 : 242 - 242
  • [9] Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
    Niesvizky, Ruben
    Wang, Luhua
    Orlowski, Robert Z.
    Bensinger, William
    Alsina, Melissa
    Gabrail, Nashat
    Gutierrez, Andres
    Kunkel, Lori
    Kauffman, Michael
    BLOOD, 2009, 114 (22) : 128 - 129
  • [10] A phase lb multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed multiple myeloma - preliminary results
    Niesvizky, R.
    Wang, M.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 569 - 569
12345